Clinician's Roundtable

Host: Gerald Watts, MD, PhD There is a high unmet need for patients with persistent chylomicronemia. Plozasiran (ARO-APOC3) is an investigational drug that is being evaluated for these patients. Professor Gerald Watts shares the outcomes of the PALISADE trial, in which the efficacy and safety of plozasiran was examined in patients with familial chylomicronemia syndrome.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Amy McMichael, MD A recent study that looked at psoriasis in patients from different races and backgrounds found that there weren’t a significant number of differences in the factors studied between patients with skin of color and Caucasian patients. The one thing that was really quite impactful for patients who are Black is that they wanted to see more physicians who could speak to their cultural and ethnic backgrounds. So to learn more about the findings and how we can address these barriers, join Dr. Charles Turck as he dives in with Dr. Amy McMichael, Professor in the Department of Dermatology at Wake Forest School of Medicine in Winston-Salem, North Carolina.

Guest: John Barbieri, MD, MBA, FAAD Patients with psoriasis die about five years younger than those without the condition, and cardiovascular disease is the leading cause of this premature mortality. Tune in to hear Dr. John Barbieri discuss strategies to identify risk factors and improve cardiovascular disease prevention in patients with psoriasis. Dr. Barbieri is an Assistant Professor of Dermatology at Brigham and Women's Hospital at Harvard Medical School in Boston.

Guest: Ina Park, MD The United States has seen its largest increase in syphilis cases in the past five years. And with increases prevalent in every region, along with a shortage of medication, additional surveillance strategies and importation resources are necessary. Dive in for a discussion on the challenges and strategies to combat the spread of syphilis with Dr. Ina Park, Professor of Family Community Medicine at the University of California San Francisco School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Melanie Dispenza, MD The future therapeutic landscape for food allergy prevention is looking clearer as a drug typically used to treat hematologic malignancies has shown to prevent systemic anaphylaxis to allergens and increase patients' tolerance to peanuts. Along with this, other therapies are also in development for allergy treatment. To learn more, join Dr. Charles Turck as he dives deeper into this study and its findings with Dr. Melanie Dispenza, Assistant Professor of Medicine at Johns Hopkins University School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Henry Rosenberg, MD Malignant hyperthermia is an inherited disorder primarily recognized by anesthesia professionals. And since this condition can have significant consequences on a patient’s health, including their likelihood of surviving surgery, it’s important to know how to diagnose and treat malignant hyperthermia emergencies in operating room settings. Join Dr. Charles Turck as he dives deeper into this topic with Dr. Henry Rosenberg, a member of the Board of Directors of the Malignant Hyperthermia Association of the United States.

Host: Charles Flexner, MD Daily oral therapy can have low adherence, which is why the field of long-acting formulations is rapidly advancing. Tune in to hear Dr. Charles Flexner discuss how long-acting regimens can address this problem of adherence and help patients living with HIV, tuberculosis, malaria, and other infectious diseases. Dr. Flexner is a Professor of Medicine of Pharmacology, Molecular Sciences, and International Health at Johns Hopkins University, and he also presented a session on this exact topic at the 2024 Conference on Retroviruses and Opportunistic Infections.

Host: Jennifer Caudle, DO Guest: Sayantani Sindher, MD Recently, Omalizumab was studied in patients due to the avoidance of management and guidance when it comes to treating food allergies in children and adults. According to this doctor, approximately 45 percent of patients seen in his clinic have multi-food allergies that are not being met with current treatment options. So to explain his research, Dr. Jennifer Caudle is joined by Dr. Sayantani Sinder, Clinical Associate Professor of Medicine and Pediatric Allergy and Clinical Immunology Physician at Stanford Healthcare and Stanford Medicine Children’s Health.

Guest: Douglas Jones, MD A recent study was done to show the side effects of diphenhydramine for allergic reactions, and one of the main detriments was that it could impair the patient by making them tired or sleepy. Another finding was that it doesn’t work that quickly, so in turn, giving diphenhydramine in a severe allergic reaction could cause more harm than good. To learn more on what you should know before using diphenhydramine in allergic reaction situations and possible better solutions, tune in with Dr. Douglas Jones, Board-Certified Allergist and Immunologist with the Tanner Clinic in Layton, Utah.

Guest: Gates B. Colbert, MD, FASN A class of medications called SGLT2 inhibitors have been proven to make a major difference for patients with chronic kidney disease (CKD) with and without diabetes when added to angiotensin converting enzyme (ACE) and angiotensin receptor blockers (ARB) classes of medications. Several medications that have been well studied and approved by the FDA in the United States have shown progression of not only CKD but also cardiovascular events and overall mortality. To learn more about these medications, join Dr. Gates Colbert, Assistant Clinical Professor of Medicine at Texas A&M College of Medicine, and Nephrologist and Certified Hypertension Specialist at Kidney and Hypertension Associates of Dallas.

Host: Michael Greenberg, MD Guest: Chris Bundy, MD, MPH, FASAM Clinicians experiencing substance abuse disorder (SUD) may have some reluctance about utilizing a Physician Health Program; however, it’s important to know what your resources are in terms of formal treatment and to seek a psychiatrist with addiction specialization. Dive into part two of this discussion to learn more about the valuable resources and programs that can help physicians recover from SUD with Dr. Michael Greenberg and Dr. Chris Bundy, Executive Medical Director of the Washington Physicians Health Program and Clinical Assistant Professor of Psychiatry at the University of Washington School of Medicine.

Host: Ashley Baker, MSN, PMHNP Guest: Chi D. Chu, MD, MAS The National Health and Nutrition Examination Survey found that kidney disease awareness among patients in the U.S. is very low. And alarmingly, the proportion of awareness has not changed much over the 15-year period of this study. To uncover more of the findings and how to improve CKD awareness, tune into this discussion with Psychiatric Nurse Practitioner Ashley Baker as she takes a deep dive with Dr. Chi D. Chu, Assistant Professor of Medicine in the Division of Nephrology at the University of California San Francisco and coauthor of the article published in the American Journal of Kidney Diseases, titled “CKD Awareness Among US Adults by Future Risk of Kidney Failure.

Host: Michael Greenberg, MD Guest: Chris Bundy, MD, MPH, FASAM Along with the general population, physicians are vulnerable to substance use disorder (SUD) with rates as high as 10 to 14 percent. And with demanding careers, stress and burnout can often exacerbate SUD. Tune into part one of this discussion with Dr. Michael Greenberg as he takes a deep dive into the prevalence of SUD and use characteristics among physicians with Dr. Chris Bundy, Executive Medical Director of the Washington Physicians Health Program and Clinical Assistant Professor of Psychiatry at the University of Washington School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Justin Reinert, PharmD Acute respiratory distress syndrome (ARDS) is a severe lung condition characterized by the rapid onset of widespread inflammation in the lungs, but inhaled epoprostenol can be used as a last-line treatment strategy for these patients. Learn more about this treatment option’s efficacy and safety with Dr. Charles Turck and Dr. Justin Reinert, Assistant Professor of Clinical Pharmacy at the University of Toledo.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Basil M. Kahwash, MD Patients with asthma could benefit greatly from exercising, and over time, it could lead to better asthma control. Dive into this episode to learn more about the findings from a recent study on exercise and asthma with Dr. Mary Katherine Cheeley and Dr. Basil Kahwash, Assistant Professor of Medicine on the Clinical Educator track in the Division of Allergy, Pulmonary, and Critical Care Medicine at Vanderbilt University in Nashville, Tennessee.

Host: Charles Turck, PharmD, BCPS, BCCCP Emerging data over the years has shown the role of GLP-1 receptor agonists, not only in terms of their initial role in managing diabetes and blood sugar but also the secondary benefit of sometimes massive amounts of weight loss. However, there hasn’t been a tremendous number of studies looking at the use of these agents in patients with HIV. Join Dr. Charles Turck as he dives into the data further with Dr. Darcy Wooten, Clinical Professor of Medicine and a Program Director for the University of California San Diego ID Fellowship Training Program in the Division of Infectious Diseases and Global Public Health.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Ananta Paine, PhD The diagnosis of psoriatic arthritis has not been easy due to the lack of knowledge about an established biomarker. To learn more, join Dr. Charles Turck as he speaks with Dr. Ananta Piane, Principal Investigator and Research Assistant Professor at the University of Rochester Medical Center in Rochester, New York, to discuss his 500-patient cohort study to find out if there are underlying differences of psoriasis patients who did not convert to psoriatic arthritis with those who did.

Host: Andrew Wilner, MD, FACP, FAAN Guest: Neil Skolnik, MD The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recently updated some of the recommendations for treating patients with chronic obstructive pulmonary disease (COPD). Two large conceptual changes occurred in this update: one is an increased emphasis on treating exacerbations, and the other is looking at decreasing mortality as an important treatment goal. Learn more about this and other key updates from the GOLD recommendations with Dr. Andrew Wilner and Dr. Neil Skolnik, Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia.

Host: Jennifer Shu, MD, FAAP Guest: Steven H. Abman, MD Bronchopulmonary dysplasia is a chronic lung disease that can have significant impacts on a newborn’s overall respiratory health, making it imperative to know how to recognize and treat it. Tune in to hear Dr. Jennifer Shu talk about the symptoms, impacts, and treatment of bronchopulmonary dysplasia with Dr. Steven Abman, a Professor in the Department of Pediatrics at the University of Colorado School of Medicine and the Director of the Pediatric Heart Lung Center at Children’s Hospital Colorado.

Host: Dalmacio Dennis Flores, PhD, ACRN, FAAN According to a Gallup poll, Generation Z youth identify as LGBTQ more than previous generations. Given this increasing prevalence, clinicians need to know how to foster synergistic relationships between parents and LGBTQ+ youth. Here to discuss this important topic is Dr. Dalmacio Dennis Flores, an Assistant Professor at the University of Pennsylvania School of Nursing. He also spoke about this exact topic at the 2023 Annual ANAC conference in his session, titled “Synergy in Inclusive Sexual Health: Triadic Models Empowering LGBTQ+ Youth, Parents, and Nurses.”